The 4 most recent market catalysts affecting $CTXR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
Citius Oncology shares are trading lower after the company reported worse-than-expected Q3 sales results.
This headline represents a direct corporate catalyst, specifically a negative earnings surprise. Worse-than-expected sales directly impact a company's revenue and profitability, le…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results.
This headline represents a significant corporate catalyst for Citius Pharmaceuticals. Worse-than-expected sales directly impact a company's revenue and profitability, leading to in…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate
Citius Pharma's Q3 earnings report presents a mixed bag for investors. While the company successfully narrowed its losses per share, beating analyst estimates, the substantial miss…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Citius Oncology shares are trading higher after the company reported a 78% quarter-over-quarter growth in new institutional accounts ordering LYMPHIR.
This headline represents a significant positive corporate catalyst for Citius Oncology. The 78% quarter-over-quarter growth in new institutional accounts ordering LYMPHIR demonstra…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.